(Adds study details)
June 25 (Reuters) – AstraZeneca Plc’s diabetes drug has significantly lowered blood sugar levels in adolescents aged 10 to 17 with type 2 diabetes in a late-stage study, the British drug maker said on Friday.
In type 2 diabetes, the body cannot use or produce the hormone insulin properly to convert blood sugar into energy.
In the study, patients who received a once-weekly dose of exenatide, sold by AstraZeneca as Bydureon, had significantly lower HbA1c levels – a measure of average blood sugar – from baseline at 24 weeks compared to placebo.
Exenatide is already approved in the United States for adult patients with type 2 diabetes.
The study data were presented at the American Diabetes Association (ADA) virtual 81st scientific sessions in 2021. (Reporting by Mrinalika Roy in Bengaluru; editing by Shinjini Ganguli)
